945P Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE): Updated results from a multi-center prospective cohort study
Year: 2021
Type: article
Source: Annals of Oncology
Authors: J. Chen, L. Lu, T-F. Wen, C-D. Lu, Y-Y. Zeng, B-D. Xiang, X. Xu, Z-Y. Huang, X-C. Li, T. Zhang, L-X. Qin
Institutions: Fudan University, Huashan Hospital, Sichuan University, West China Hospital of Sichuan University, Ningbo University, Ningbo Medical Center Lihuili Hospital, Fujian Medical University, Mengchao Hepatobiliary Hospital, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, Zhejiang University, Tongji Hospital, Huazhong University of Science and Technology, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Province Hospital, Fudan University Shanghai Cancer Center
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3204614425